AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Incretin-Based Therapies in Obesity-Related Heart Failure with Preserved Ejection Fraction

By Jundi I, Gaines H, Patsias I

Recent randomized trials of incretin-based therapies have shown benefit in obesity-related heart failure with preserved ejection fraction (HFpEF). Whether benefits extend across incretin classes and across diabetic status and sex strata has not been formally synthesized. Hypothesis: Incretin-based therapy reduces cardiovascular death or worsening heart failure in obesity-related HFpEF, with consistent effects across diabetic status, sex, and pharmacologic class. Methods: We conducted a PRISMA 2020-compliant systematic review and meta-analysis of randomized trials of GLP-1 and dual GIP/GLP-1 receptor agonists in HFpEF (PROSPERO CRD420261384100). The primary composite of cardiovascular death or worsening heart failure events was pooled by fixed-effect synthesis of trials meeting prespecified hard-endpoint criteria. Functional outcomes (KCCQ-CSS, 6-minute walking distance, body weight, hsCRP) across the three dedicated HFpEF trials were pooled using fixed-effect or DerSimonian-Laird random-effects with HKSJ adjustment as indicated. Cross-class comparison used Bucher-style indirect methodology. Cross-method comparison referenced the Kosiborod 2024 participant-level pooled analysis. Certainty was assessed using GRADE. Results: Two trials met the hard-endpoint criteria (SUMMIT and the prespecified SELECT-HFpEF subgroup; n=3,004), yielding a pooled hazard ratio of 0.69 (95% CI 0.53-0.91, p=0.008), concordant with the Kosiborod 2024 participant-level estimate (HR 0.69, 95% CI 0.53-0.89; n=3,743). A prespecified K=4 sensitivity pool adding sparse-event STEP hazard ratios was directionally consistent (HR 0.65, 95% CI 0.50-0.84). The composite signal reflects worsening heart failure rather than cardiovascular mortality. Across the three dedicated HFpEF trials (n=1,876), pooled estimates were +7.4 points (95% CI 5.5-9.3) for KCCQ-CSS, +17.6 m (95% CI 11.9-23.4) for 6-minute walking distance, –9.6% (95% CI –16.5 to –2.7) for body weight, and 0.63 (95% CI 0.58-0.70) for hsCRP ratio. Treatment effects on heart-failure-relevant outcomes were consistent across diabetic status and sex; the only significant interaction was for body weight (larger in non-diabetic participants and in women). Adjusted indirect comparison between tirzepatide and semaglutide yielded a ratio of 0.83 (95% CI 0.48-1.44, p=0.50), insufficient to establish class superiority. Conclusions: Incretin-based therapies reduce cardiovascular death or worsening heart failure events in obesity-related HFpEF, driven by morbidity reduction. Symptom, exercise, weight, and inflammation benefits are substantial in magnitude and consistent across diabetic status and sex. Whether incretin-based therapies improve cardiovascular mortality or differ meaningfully by molecular class in HFpEF remains uncertain and requires dedicated mortality-powered trials.

doi.org/10.1161/circ.154.suppl_1.5558Interventions

AgingResearch.News